Uncategorized

Congestive Heart Failure (CHF) Market Trends 2025–2029: Forecasts for Key Growth Segments

November 26, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Congestive Heart Failure (CHF) Market Expected To Expand Between 2025 And 2029?

The congestive heart failure (chf) market size has shown substantial growth in recent years. This market is set to expand from $15.94 billion in 2024 to $16.94 billion in 2025, reflecting a compound annual growth rate (CAGR) of 6.3%. The factors contributing to this historical growth include the high prevalence of an aging population, the increasing incidence of cardiovascular diseases, a rise in awareness regarding heart health, growing healthcare expenditure, and an increasing demand for remote patient monitoring.

The congestive heart failure (CHF) market is anticipated to experience substantial expansion in the coming years. Its valuation is projected to reach $21.79 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.5%. This projected growth during the forecast period is primarily driven by factors such as the increasing uptake of digital health solutions, a higher incidence of hypertension, escalating obesity rates, enhanced patient outcomes, and a greater emphasis on personalized medicine. Key trends expected over the forecast period encompass progress in diagnostic technologies, improvements in treatment alternatives, technological strides in medical imaging, novel therapeutic innovations, and the evolution of wearable health devices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20730&type=smp

What Are The Key Drivers Of Growth In The Congestive Heart Failure (CHF) Market?

The increasing number of cardiovascular patients is anticipated to drive the expansion of the congestive heart failure (CHF) market moving forward. Cardiovascular refers to the heart and blood vessels, highlighting their role in blood circulation and maintaining general bodily health. The growth in cardiovascular patients is attributed to inactive lifestyles, poor dietary choices, an aging demographic, and urbanization, which collectively elevate the demand for advanced healthcare and treatment options. Congestive heart failure (CHF) offers valuable, targeted solutions for cardiovascular patients by improving heart efficiency, reducing symptoms, and averting complications, ultimately enhancing patient care and overall well-being. For instance, in January 2023, the American College of Cardiology, a US-based nonprofit medical society, noted that cardiovascular disease cases rose to 19.8 million in 2022. Additionally, Eastern Europe registers the highest mortality rate, at 553 deaths per 100,000. Consequently, the rising prevalence of cardiovascular patients is stimulating growth within the congestive heart failure (CHF) market.

What Are The Primary Types Of Segments Analyzed In The Congestive Heart Failure (CHF) Market?

The congestive heart failure (chf)market covered in this report is segmented –

1) By Type: Systolic Heart Failure; Diastolic Failure; Left-Sided Heart Failure; Right-Sided Heart Failure

2) By Treatment: Medication; Surgery

3) By Diagnosis: Electrocardiogram; Echocardiogram; Magnetic Resonance Imaging (MRI); Stress Test; Blood Tests; Cardiac Catheterization; Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Homecare Settings

Subsegments:

1) By Systolic Heart Failure: Reduced Ejection Fraction (HFrEF); Mild-to-moderate Reduced Ejection Fraction

2) By Diastolic Heart Failure: Preserved Ejection Fraction (HFpEF); Borderline Ejection Fraction (HFpEF)

3) By Left-Sided Heart Failure: Acute Left-Sided Heart Failure; Chronic Left-Sided Heart Failure

4) By Right-Sided Heart Failure: Acute Right-Sided Heart Failure; Chronic Right-Sided Heart Failure

What Long-Term Trends Will Shape The Future Growth Of The Congestive Heart Failure (CHF) Industry?

Leading companies active in the congestive heart failure (CHF) market are concentrating on advanced innovations, such as single intracoronary infusion therapies, to provide effective treatment options that enhance heart function and improve the quality of life for CHF patients. Single intracoronary infusion delivers medicine directly into the coronary artery, targeting the heart to offer precise treatment for conditions like congestive heart failure (CHF). For instance, in January 2024, Bayer AG, a Germany-based pharmaceutics company, and Asklepios Biopharmaceutical, Inc., a US-based biotechnology company, initiated the GenePHIT Phase II trial for AB-1002, an investigational gene therapy designed for congestive heart failure (CHF). This innovation employs a gene therapy approach to target non-ischemic cardiomyopathy, potentially offering a breakthrough in CHF treatment through advanced genetic solutions. The trial is adaptive, double-blind, placebo-controlled, and aims to enroll between 90 and 150 participants who have been medically stable for at least four weeks and have a left ventricular ejection fraction between 15% and 35%.

Who Are The Major Companies Operating In The Congestive Heart Failure (CHF) Market?

Major companies operating in the congestive heart failure (CHF) market are Pfizer Inc., Johnson & Johnson Inc., Boehringer Ingelheim International GmbH, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG., Medtronic Plc, Eli Lilly and Company, Canon Medical Systems Corporation, Novo Nordisk A/S, Jarvik Heart Inc., Boston Scientific Corporation, Applied Molecular Genetics Inc., Biotronik SE & Co. KG, Exelixis Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., LivaNova

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/congestive-heart-failure-chf-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Congestive Heart Failure (CHF) Market?

North America was the largest region in the congestive heart failure (CHF) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure (CHF) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Congestive Heart Failure (CHF) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20730&type=smp

Browse Through More Reports Similar to the Global Congestive Heart Failure (CHF) Market 2025, By The Business Research Company

Prosthetic Heart Valve Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/prosthetic-heart-valve-devices-and-equipment-global-market-report

Heart Attack Diagnostic Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/heart-attack-diagnostic-global-market-report

Implantable Heart Pacemaker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/implantable-heart-pacemaker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795